If you take blood-pressure medications (ACE inhibitors, ARBs, or potassium-sparing diuretics), have kidney disease, or take NSAIDs regularly, potassium testing is essential—these medications and conditions directly alter potassium handling. Even without medication, renal disease silently disrupts potassium balance before you feel symptoms. Abnormal potassium creates dangerous cardiac arrhythmias and can precipitate sudden cardiac events, making it one of the few biomarkers where "normal" is not merely desirable but critical for safety.

Potassium is less talked about than lipids or glucose, but it is more immediately dangerous than either. A person with high cholesterol feels nothing; a person with severe hyperkalemia may develop sudden fatal arrhythmia. This is a marker that earns routine screening, particularly if you have risk factors for kidney disease or take medications that affect renal potassium excretion.

• Detects dangerous cardiac electrolyte shifts early. Hypokalemia and hyperkalemia both disrupt the cardiac action potential and trigger life-threatening arrhythmias before symptoms appear. Testing catches these before they become emergencies.

• Guides medication safety. ACE inhibitors, ARBs, NSAIDs, and potassium-sparing diuretics all raise potassium risk. Loopi testing paired with medication review prevents iatrogenic hyperkalemia, a common cause of hospital admission.

• Reveals hidden kidney dysfunction. Chronic kidney disease progresses silently in early stages; potassium elevation often signals declining renal function before creatinine or eGFR change. Testing potassium alongside creatinine and eGFR provides early warning.

• Flags magnesium depletion. Hypokalemia driven by magnesium deficiency is refractory to potassium supplementation alone—the magnesium must be repleted. Testing potassium alongside magnesium reveals this dual deficit.

• Tracks dietary and metabolic imbalances. Severe vomiting, diarrhoea, or diuretic use causes potassium wasting; disordered eating or laxative abuse creates potassium depletion patterns visible on testing. Hyperkalemia signals acidosis or sudden cell breakdown.

• Validates acid-base disturbances. Metabolic acidosis shifts potassium out of cells, raising serum levels acutely. Metabolic alkalosis drives potassium into cells, lowering serum levels. Potassium paired with blood gas and electrolyte panels reveals the full acid-base picture.

The biology of cellular electrical potential. Potassium is the main intracellular cation—98% of the body's potassium resides inside cells, where it works with sodium to generate the electrical gradient that drives neuromuscular and cardiac excitability. The Na+/K+ ATPase pump continuously extrudes sodium and reabsorbs potassium, burning roughly 30% of the body's ATP in the process. Serum potassium—the 2% outside cells—is the critical variable that determines the resting membrane potential. Even a 0.5 mmol/L shift from 4.0 to 4.5 mmol/L makes cells more irritable; larger shifts cause cardiac dysrhythmias.

Why the reference range is so narrow and critical. Unlike most biomarkers with wide normal ranges, potassium is tightly controlled because even small changes are biologically consequential. The kidneys excrete roughly 90% of dietary potassium via the distal tubule and collecting duct, regulated by aldosterone. When potassium rises, aldosterone secretion increases, driving urinary potassium excretion. When potassium falls, aldosterone drops, triggering reabsorption. This feedback loop is exquisitely sensitive. Drugs that block aldosterone (ACE inhibitors, ARBs, spironolactone), kidney disease that impairs distal tubule function, or acute cell breakdown (rhabdomyolysis, tumour lysis, haemolysis) overwhelm this regulatory system, raising serum potassium acutely.

The practical peril of hemolysis. Serum potassium is commonly elevated falsely by hemolysis—rupture of red blood cells during or after blood collection. Because red cells are packed with potassium, even minor hemolysis releases enough to raise serum levels 0.5–1.0 mmol/L above the true value. This is the most common reason for isolated hyperkalemia in an otherwise well patient. Experienced phlebotomists and labs recognize hemolysis visually (pink-tinged serum) and recommend recollection. Hemolysis is a preanalytical error, not a true biomarker abnormality—always verify a surprisingly high potassium with a recollected, non-hemolysed sample.

• Sudden cardiac death prevention. Severe hypokalemia (<2.5 mmol/L) and severe hyperkalemia (>6.5 mmol/L) are medical emergencies that cause life-threatening ventricular arrhythmias. Hyperkalemia kills faster—potassium >7 mmol/L can trigger cardiac arrest within hours. Unlike high cholesterol or slightly elevated glucose, potassium abnormality is immediately dangerous.

• Early detection of kidney disease. In early chronic kidney disease (eGFR 60–30), serum creatinine and eGFR may still look normal, but potassium begins to climb because the kidneys lose distal tubule function before proximal clearance fails. Potassium elevation often precedes creatinine rise, making it an early-warning marker for renal decline.

• Medication-induced hyperkalemia is preventable. ACE inhibitors, ARBs, and NSAIDs together create a perfect storm for potassium retention, especially in older adults or those with mild renal impairment. Many clinicians are unaware of the cumulative risk. Testing potassium every 6–12 months in a patient on these drugs prevents iatrogenic hyperkalemia and its deadly consequences.

• Hypokalemia reveals multi-system dysfunction. True hypokalemia (<3.5 mmol/L) is uncommon in healthy people eating adequate dietary potassium. When it occurs, it signals thiazide or loop diuretic use, GI losses, hyperaldosteronism, refeeding syndrome, or severe magnesium depletion. Detecting it prompts investigation and prevents lethal arrhythmias and sudden death, particularly in older adults on diuretics.

• Standard Swedish clinical reference (3.5–5.0 mmol/L): This is the range reported by vårdcentraler and Swedish clinical labs. Values within this range are considered safe by conventional standards and do not trigger urgent clinical action.

• Loovi optimal (longevity baseline) for healthy adults: 4.0–4.8 mmol/L. This narrower range sits comfortably in the middle of the standard reference and reflects potassium levels associated with lowest arrhythmia risk in primary prevention cohorts. Levels consistently <3.5 or >5.0 warrant investigation.

• Aggressive tier (established cardiovascular disease or chronic kidney disease): 4.2–4.9 mmol/L. In patients with heart failure, prior myocardial infarction, or Stage 3–4 CKD, cardiologists often target tighter control because even small potassium shifts increase arrhythmia risk in a damaged heart or in the setting of impaired renal excretion.

The shift from 3.5 to 4.0 mmol/L and from 5.0 to 5.5 mmol/L represents progressively higher arrhythmia risk in longitudinal studies. A person at 3.2 mmol/L (low-normal) or 5.3 mmol/L (high-normal) is at measurably higher risk than someone at 4.0 mmol/L, particularly if they also have cardiac disease, are on QT-prolonging drugs, or have hypomagnesemia. For primary prevention longevity, aiming for 4.0–5.0 mmol/L is most protective.

Low (<3.5 mmol/L, hypokalemia). Serum potassium <3.5 mmol/L indicates net potassium loss or insufficient intake. In otherwise healthy people eating adequate vegetables and fruit, hypokalemia is unusual and warrants investigation. Common causes include thiazide or loop diuretic use (for hypertension or heart failure), severe vomiting or diarrhoea, villous adenoma or chronic laxative abuse, or hyperaldosteronism. A critical finding: hypokalemia paired with normal or low-normal magnesium is particularly dangerous—magnesium depletion prevents potassium repletion, creating refractory hypokalemia. If serum magnesium is <0.75 mmol/L alongside potassium <3.5, both must be corrected.

Optimal (3.5–5.0 mmol/L, euthyroid). This is the safe, normal reference range. For primary prevention and longevity, aiming for the middle tier (4.0–4.8 mmol/L) is ideal. People in this range typically have preserved kidney function, are not on potassium-affecting drugs (or are managed carefully if they are), and maintain adequate dietary intake of fruit, vegetables, and whole grains. Serial potassium testing in this range every 12 months is reassuring; no urgent action needed.

High-normal (5.0–5.5 mmol/L). This tier warrants attention but not panic. Values of 5.1–5.5 mmol/L suggest early potassium accumulation, often from mild renal impairment (eGFR 45–60), use of ACE inhibitors or ARBs without recent monitoring, NSAIDs in the context of renal disease, or dietary potassium loading (very high intake of potassium-rich foods paired with reduced urine output). A single result in this range in an otherwise well person is often transient; retest to confirm. If consistently >5.0 mmol/L, investigate: repeat serum potassium (excluding hemolysed samples), check creatinine and eGFR, review medications, and assess acid-base status (acidosis raises potassium).

Elevated (5.5–6.5 mmol/L, hyperkalemia). Sustained serum potassium >5.5 mmol/L is abnormal and requires clinical evaluation. At 5.5–6.0 mmol/L, ECG changes may appear (peaked T waves). Above 6.0 mmol/L, cardiac arrhythmia risk rises steeply. Causes include chronic kidney disease (especially Stage 4–5, eGFR <30), combined use of ACE inhibitor/ARB plus potassium-sparing diuretic or NSAID, Type 1 diabetes with renal disease, adrenal insufficiency, or severe acidosis. This level demands urgent medication review and potentially dietary potassium restriction. Some patients require potassium-binding resins or diuretics to lower levels acutely.

Very high (>6.5 mmol/L, severe hyperkalemia). Potassium >6.5 mmol/L is a medical emergency. ECG changes worsen, cardiac arrhythmia is imminent, and sudden cardiac arrest is a real risk. This level typically reflects acute kidney injury, massive cell breakdown (rhabdomyolysis, tumour lysis, haemolysis), acute acidosis, or combined medication effects in someone with underlying renal disease. Immediate clinical intervention is required—IV calcium (membrane stabilization), insulin with glucose (shifts potassium intracellularly), beta-agonists (shifts potassium in), and potassium-binding agents or dialysis may all be necessary.

Factors that influence potassium. Intense exercise causes transient potassium release from muscle; potassium can rise 0.5–1.0 mmol/L during or immediately after vigorous training, returning to baseline within minutes to hours. Acidosis (from any cause) raises serum potassium by shifting it out of cells; metabolic acidosis with pH <7.2 can raise potassium 0.5–1.0 mmol/L acutely, which normalizes when acid-base status improves. Alkalosis lowers potassium by shifting it into cells. Hemolysis during blood draw falsely elevates potassium; visible hemolysis should prompt recollection. Pseudohypoaldosteronism or collecting duct dysfunction from NSAIDs or ACE inhibitors/ARBs sustains hyperkalemia. Diuretic use is powerful: loop and thiazide diuretics lower potassium via increased urinary excretion, while potassium-sparing diuretics (spironolactone, amiloride) raise it. Insulin therapy lowers potassium by driving glucose and potassium into cells. Time of day and posture are minor factors; potassium is most stable when samples are collected in the morning, fasted, after 5 minutes of seated rest.

• Kidney disease and renal dysfunction. The kidneys excrete 90% of dietary potassium. When glomerular filtration declines (eGFR <60), distal tubule dysfunction begins, and potassium accumulates. Chronic kidney disease is the most common cause of hyperkalemia in practice. In Stage 3–4 CKD, even normal dietary potassium intake can raise serum levels. This is a core reason why potassium testing is standard in anyone with reduced eGFR.

• Medications: ACE inhibitors, ARBs, NSAIDs, and potassium-sparing diuretics. These drugs raise potassium by inhibiting aldosterone or reducing renal perfusion pressure, impairing distal tubule potassium secretion. ACE inhibitors and ARBs alone raise potassium modestly (0.3–0.5 mmol/L on average). Combined with NSAIDs (which further reduce renal perfusion) or a potassium-sparing diuretic, the effect is synergistic and dangerous. Hyperkalemia from drug combinations is often iatrogenic and preventable with regular monitoring.

• Hypokalemia from diuretics and GI losses. Loop diuretics (furosemide) and thiazide diuretics increase distal sodium delivery and urine flow, driving potassium wasting. Chronic diarrhoea (inflammatory bowel disease, celiac disease, chronic laxative abuse) causes potassium depletion. Severe vomiting causes loss of both potassium and magnesium. Villous adenomas secrete mucus with high potassium content. These are the main causes of true hypokalemia in primary care.

• Dietary potassium intake and metabolic factors. Adequate dietary potassium (from fruit, vegetables, legumes, whole grains, fish) is protective; low-intake diets elevate hypokalemia risk. Conversely, very high dietary potassium intake (supplemental potassium pills, potassium salt substitutes) combined with renal impairment or potassium-sparing drugs causes hyperkalemia. Acid-base status is critical: metabolic acidosis raises potassium acutely; metabolic alkalosis lowers it. Insulin deficiency (Type 1 diabetes, DKA) impairs potassium uptake into cells, raising serum levels.

• Cell breakdown and tissue injury. Rhabdomyolysis (crush injury, intense exertion, statin myopathy), tumour lysis syndrome (after chemotherapy), severe haemolysis, or myocardial infarction all release intracellular potassium, causing acute hyperkalemia. These are emergency presentations, but the underlying mechanism—massive intracellular potassium release—is important to recognize.

Dietary approach and food sources. For people with normal kidney function and not on potassium-raising medications, maintaining adequate dietary potassium is the foundation. Potassium-rich foods include leafy greens (spinach, kale), cruciferous vegetables (broccoli, Brussels sprouts), legumes (lentils, beans), whole grains, avocado, salmon, and nuts. A DASH-style dietary pattern (high in vegetables, fruit, whole grains, and legumes) delivers 3000–4000 mg potassium daily and is associated with lower blood pressure and cardiovascular risk. This is a mechanism not a prescription: adequate dietary potassium is part of the evidence-based framework for cardiovascular health. People with kidney disease or on potassium-raising drugs must restrict potassium and work with a nephrologist or dietitian—high dietary potassium in this context is dangerous.

Avoid potassium-depleting behaviours. Chronic diuretic use (for hypertension or heart failure) drives potassium wasting; this requires regular monitoring and sometimes concurrent potassium supplementation or potassium-sparing drugs to maintain balance. Laxative abuse and severe caloric restriction both impair potassium retention. Alcohol excess causes diarrhoea and magnesium depletion, which secondarily lowers potassium. Intense exercise without adequate potassium intake can worsen depletion, particularly in people on diuretics.

Manage medication synergies carefully. If you take an ACE inhibitor or ARB for blood pressure or heart protection, avoid concurrent NSAID use if possible—the combination dramatically raises hyperkalemia risk. If NSAIDs are necessary, use them only briefly and retest potassium 1–2 weeks later. Do not combine ACE inhibitor + ARB + potassium-sparing diuretic without close monitoring; this triple combination is high-risk. Potassium-sparing diuretics (spironolactone) are sometimes indicated for heart failure, but they require regular serum potassium checks because hyperkalemia can develop insidiously.

Optimize renal function and acid-base status. Maintaining eGFR through blood-pressure control, avoiding nephrotoxic drugs, and managing diabetes reduces potassium accumulation. Severe acidosis raises potassium acutely; correcting the underlying cause (metabolic acidosis from kidney disease, diabetic ketoacidosis, etc.) allows potassium to normalize. Blood-pressure control itself reduces potassium dysregulation because stable renal perfusion pressure preserves distal tubule function.

Magnesium sufficiency is essential. Magnesium depletion prevents potassium repletion—it is impossible to fix hypokalemia without correcting concurrent hypomagnesemia. Magnesium regulates ROMK channels in the distal tubule; without sufficient magnesium, potassium leaks into urine despite supplementation. People on chronic diuretics or with GI disease are at high risk for dual magnesium-potassium depletion. Paired testing of magnesium alongside potassium is essential for proper interpretation and treatment.

The right intervention depends on your baseline potassium, kidney function (creatinine and eGFR), medications, and dietary intake—precisely the personalized synthesis that a Loovi longevity doctor evaluates in consultation. Potassium is not a "take this supplement" marker; it requires integrated assessment of renal function, medication effects, and acid-base status to optimize safely.

Potassium alone tells an incomplete story. A person with potassium 5.2 mmol/L and eGFR 65 mL/min/1.73m² (Stage 2 CKD) may have mild early renal potassium retention that is manageable with dietary adjustment. The same potassium value in someone with eGFR 25 mL/min/1.73m² (Stage 4 CKD) represents dangerous accumulation requiring medication review and possible intervention. Potassium must always be interpreted alongside creatinine and eGFR to understand kidney function context. Similarly, hyperkalemia in the setting of metabolic acidosis (pH <7.25) is more urgent than the same potassium value in someone with normal pH—the acid-base status changes interpretation. Medications like ACE inhibitors, ARBs, NSAIDs, and spironolactone must also be on the table when interpreting abnormal potassium, because the drug context drives the clinical decision.

Testing sodium alongside potassium reveals fluid-balance disorders—combined hyponatremia and hypokalemia suggests significant GI losses or diuretic excess. Testing magnesium is essential: concurrent hypomagnesemia (<0.75 mmol/L) makes hypokalemia refractory to potassium replacement alone; you must replete both. Testing urea and eGFR provides essential context on renal function and metabolic state. These clusters of markers—potassium, sodium, creatinine, eGFR, magnesium, urea—form the foundation of renal and metabolic assessment.

The Loovi Membership measures 120+ biomarkers annually, including the full electrolyte panel (sodium, potassium, magnesium), comprehensive renal markers (creatinine, eGFR, urea), acid-base status, and all the adjacent systems that influence potassium balance. Paired with unrushed 1-on-1 longevity doctor consultations where medications are reviewed in context of your full biomarker profile, physical performance tests (strength, mobility, VO2 max), and an evolving personalized health plan, Loovi ensures your potassium is optimized as part of an integrated whole-body assessment. From 295 SEK/month, Friskvårdsbidrag-approved, with drop-in testing at 80+ Swedish clinics and results in 3 days.